It plays a crucial role in mediating UA reabsorption, a process in which approximately 90% of uric acid is typically reabsorbed following glomerular filtration
HU-6 is a CMA, administered orally once a day, currently under development for the treatment of obesity and related complications, such as T2DM, MASH, severe hypertriglyceridemia, and heart failure with preserved ejection fraction (HFpEF) ( The HuMAIN study, a phase 2a trial examining HU-6 in subjects with HFpEF shows a mean weight loss of 3.1kg compared to 0.2 kg for the placebo group at three months ( 7 Melanocortin 4 receptor agonists 7.1 Setmelanotide Setmelanotide is a melanocortin-4 receptor (MC4R) agonist that is administered subcutaneously once a day ( It is being investigated for treatment of various heterozygous mutations in LepR, POMC, or PCSK1 genes, and homozygous or heterozygous mutations in the steroid receptor coactivator-1 (SRC1) or SH2B adapter protein 1 (SH2B1) genes ( Setmelanotide is currently being studied for treatment of acquired hypothalamic obesity (HO), a condition occurring after injury to the relevant satiety centers, also characterized by hyperphagia and rapid weight gain
Ainsworth NJ, Oughli H, Lavretsky H, Blumberger DM, Brown PJ, Butters MA, et al
doi: 10.1093/humrep/dem271
First-quarter growth was heavily driven by GLP-1 sales growth in diabetes (32%, mostly from Ozempic) and obesity (42%, mostly from Wegovy)
